Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Abandoned drugs
NS-2359
Другие языки:

    NS-2359

    Подписчиков: 0, рейтинг: 0
    NS-2359
    NS-2359 Structure.svg
    Clinical data
    ATC code
    • none
    Identifiers
    • (1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
    PubChem CID
    UNII
    Chemical and physical data
    Formula C15H19Cl2NO
    Molar mass 300.22 g·mol−1
    3D model (JSmol)
    • Clc1ccc(cc1Cl)C(C2COC)CC3NC2CC3
      (verify)

    NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant, but was discontinued in 2009 when phase II clinical trials showed the drug was not effective and not well tolerated. The results did not support further effort by the company. NS-2359 was also in clinical trials for the treatment of ADHD, phase II having been completed in 2007. A phase I clinical trial exploring the effect of NS-2359 on cocaine-dependent individuals was completed in 2002.

    See also


    Новое сообщение